Want to see IN:ENTERO full AI Analyst Report?
ENTERO Stock Chart & Stats
₹1230.80
₹43.80(3.56%)
At close: 4:00 PM EDT
₹1230.80
₹43.80(3.56%)
Day’s Range― - ―
52-Week Range₹944.00 - ₹1,919.25
Previous CloseN/A
Volume165.84K
Average Volume (3M)74.09K
Market Cap
₹75.43B
Enterprise Value₹58.72K
Total Cash (Recent Filing)₹2.92B
Total Debt (Recent Filing)₹6.77B
Price to Earnings (P/E)60.1
Beta0.62
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.44
Shares Outstanding43,523,070
10 Day Avg. Volume53,834
30 Day Avg. Volume74,091
Financial Highlights & Ratios
PEG Ratio2.22
Price to Book (P/B)3.22
Price to Sales (P/S)0.82
P/FCF Ratio3.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,800.00Price Target Upside46.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)39.95
Revenue Forecast (FY)₹82.40B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue has expanded substantially across four fiscal years, demonstrating increasing scale in Entero’s healthcare distribution network. Continued volume growth can support broader customer reach, better utilization of infrastructure, and stronger earnings capacity if the company preserves disciplined working-capital management.
Return To ProfitabilityThe move from losses to positive net income represents a meaningful improvement in the operating model. Sustained profitability would strengthen internally generated capital, improve financial resilience, and provide a foundation for continued expansion across pharmaceutical and allied healthcare distribution.
Equity SupportA sizable equity base provides support for the company’s balance sheet and helps absorb the funding demands of a distribution business. Although leverage has increased, current debt remains moderate relative to equity, preserving some capacity to finance operations and growth.
Bears Say
Thin MarginsLow margins leave limited room to absorb pricing pressure, operating cost increases, or execution errors. Because small changes in gross profitability can materially affect net income, the business needs sustained scale and cost discipline to protect earnings over the coming quarters.
Weak Cash ConversionNear break-even free cash flow indicates that reported earnings are not yet translating into substantial financial flexibility. Working-capital intensity or reinvestment needs may continue to absorb cash, limiting funds available for debt reduction, expansion, or shareholder returns.
Rising LeverageHigher debt increases the company’s financial obligations while cash generation remains weak, making the balance sheet more sensitive to operating setbacks. The latest available ROE was only about 5.5%, so returns have not yet clearly justified the added leverage burden.
Entero Healthcare Solutions Limited News
ENTERO FAQ
What was Entero Healthcare Solutions Limited’s price range in the past 12 months?
Entero Healthcare Solutions Limited lowest stock price was ₹944.00 and its highest was ₹1919.25 in the past 12 months.
What is Entero Healthcare Solutions Limited’s market cap?
Entero Healthcare Solutions Limited’s market cap is ₹75.43B.
When is Entero Healthcare Solutions Limited’s upcoming earnings report date?
Entero Healthcare Solutions Limited’s upcoming earnings report date is Nov 18, 2026 which is in 57 days.
How were Entero Healthcare Solutions Limited’s earnings last quarter?
Entero Healthcare Solutions Limited released its earnings results on Aug 07, 2026. The company reported ₹8.8 earnings per share for the quarter, beating the consensus estimate of ₹6.8 by ₹2.
Is Entero Healthcare Solutions Limited overvalued?
According to Wall Street analysts Entero Healthcare Solutions Limited’s price is currently Undervalued.
Does Entero Healthcare Solutions Limited pay dividends?
Entero Healthcare Solutions Limited does not currently pay dividends.
What is Entero Healthcare Solutions Limited’s EPS estimate?
Entero Healthcare Solutions Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entero Healthcare Solutions Limited have?
Entero Healthcare Solutions Limited has 43,523,070 shares outstanding.
What happened to Entero Healthcare Solutions Limited’s price movement after its last earnings report?
Entero Healthcare Solutions Limited reported an EPS of ₹8.8 in its last earnings report, beating expectations of ₹6.8. Following the earnings report the stock price went up 0.314%.
Which hedge fund is a major shareholder of Entero Healthcare Solutions Limited?
Currently, no hedge funds are holding shares in IN:ENTERO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entero Healthcare Solutions Limited
Established in 2018 and headquartered in Mumbai, India, Entero Healthcare Solutions Limited functions as a key distributor within the Indian healthcare sector. The company specializes in supplying a diverse range of medical and health-related products, including pharmaceuticals, surgical instruments, medical equipment, over-the-counter remedies, nutritional supplements, and vaccines. Its extensive client base spans retail pharmacies, hospitals, nursing homes, and various healthcare clinics throughout the country.
ENTERO Stock 12 Month Forecast
Average Price Target
₹1,800.00
▲(46.25% Upside)
Technical Analysis
Artemis Medicare Services Ltd.
―
Bliss Gvs Pharma Limited
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Unichem Laboratories Limited
―







